Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Biocytogen Pharmaceuticals has entered into a strategic collaboration with SOTIO Biotech to develop next-generation antibody-drug conjugates for solid tumor treatment, involving Biocytogen’s RenLite platform and SOTIO’s ADC platform. The agreement could yield Biocytogen up to $325.5 million in upfront and milestone payments, plus royalties on net sales. While SOTIO will handle the development, manufacturing, and commercialization, the companies will work jointly in the research phase.
For further insights into HK:2315 stock, check out TipRanks’ Stock Analysis page.